{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-23-000085","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.419386+00:00","generated_at":"2026-06-08T17:47:54.824343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mineralys Q3 net loss $22.8M; cash $265.9M; Phase 3 Launch-HTN start on track for 2H2023, topline delayed to 2H2025","bullets":["Net loss $22.8M (Q3 2023) vs $6.7M (Q3 2022); R&D expenses $22.5M, up from $6.1M.","Cash, cash equivalents and investments $265.9M as of Sep 30, 2023; expected to fund operations through mid-2025.","Advance-HTN topline data revised from 1H2024 to 2H2024 due to protocol amendment and enrollment curve.","Phase 3 Launch-HTN trial remains on track to initiate in 2H2023; topline data now expected in 2H2025.","Explore-CKD Phase 2 trial expected to start in 2H2023 with topline data in Q4 2024–Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-23-000085","json":"https://secwatch.observer/filing/0001933414-23-000085.json","markdown":"https://secwatch.observer/filing/0001933414-23-000085.md","text":"https://secwatch.observer/filing/0001933414-23-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/0001933414-23-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/mlys-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:47:54.824343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86475ac1b70763afe7afb3bacda3384861096141","claim":"Mineralys Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000085/0001933414-23-000085-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}